The University of Antwerp in Belgium has initiated an innovative clinical trial aimed at mitigating the cognitive deficits associated with breast cancer treatment, marking a significant advancement in the field. This trial will utilize a video game-based training and assessment tool, scientifically designed by the UK-based My Cognition, which specializes in cognitive health.

Addressing Cognitive Impacts of Breast Cancer Treatment

Historically, breast cancer research has predominantly focused on eradicating tumors and managing the physical spread of the disease. However, the cognitive side effects of breast cancer treatments, commonly referred to as “chemo-fog,” have increasingly become a concern. An estimated 30% of breast cancer patients experience cognitive impairments due to the neurotoxic effects of treatment, which can significantly diminish their quality of life.

Dr. Anne Bellens from the University Hospital of Antwerp emphasized the importance of this trial, stating, “Breast cancer sufferers often experience a reduced quality of life after treatment completion. This new approach offers people with breast cancer hope that an intervention could be effective in assessing and minimizing the cognitive impact of the disease in patients, significantly improving their quality of life.”

Innovative Approach with MyCognition’s Tools

The clinical trial will be the first of its kind to employ a clinically validated, non-invasive medical device in the form of a cognitive assessment tool combined with a video game. MyCognition’s platform is designed to not only assess but also enhance cognitive functioning through targeted training.

Keiron Sparrowhawk, founder and CEO of MyCognition, shared his enthusiasm for the project: “MyCognition’s mission has been to help individuals with cognitive deficits. We are proud to be working with Dr. Anne Bellens to carry out this ground-breaking clinical trial, which we hope will change the lives of patients by improving their cognitive function through the use of MyCQ.”

Trial Structure and Expectations

The trial will involve 40 female breast cancer patients who will undergo cognitive assessments using My Cognition’s tools. Half of these participants will complete a series of training sessions using the video game. The outcomes of this study, expected to be published between 2017 and 2018, aim to enhance understanding of how breast cancer treatments affect cognition and explore potential improvements post-treatment.

The University of Antwerp’s clinical trial represents a critical step forward in addressing the often-overlooked cognitive side effects of breast cancer treatment. By integrating innovative technology with clinical research, the trial not only seeks to improve cognitive functions but also aims to enhance overall patient care and quality of life. This approach could potentially set a new standard in the treatment and care of breast cancer patients.

  Breast Cancer, breast cancer treatment, chemo-fog, clinical trial, cognitive deficits, Cognitive Impairment, My Cognition, non-invasive medical device, The University of Antwerp, University of Antwerp